Literature DB >> 8018111

Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study.

G Alfthan1, J Pekkanen, M Jauhiainen, J Pitkäniemi, M Karvonen, J Tuomilehto, J T Salonen, C Ehnholm.   

Abstract

The relation of serum total homocysteine and lipoprotein(a) (Lp(a)) with the incidence of atherosclerotic disease was investigated among 7424 men and women aged 40-64 years free of atherosclerotic disease at baseline in 1977. During the 9-year follow-up, 134 male and 131 female cases with either myocardial infarction or stroke were identified. For each case a control subject was selected belonging to the same sex and 5-year age group. Serum samples collected in 1977 were stored at -20 degrees C and analyzed in 1991. The mean serum homocysteine concentration of male cases and controls was 9.99 mumol/l and 9.82 mumol/l at baseline and that of female cases and controls 9.58 mumol/l and 9.24 mumol/l, respectively. The median serum Lp(a) concentration of male cases and controls was 73 mg/l and 108 mg/l and that of female cases and controls 113 mg/l and 91 mg/l, respectively. The differences between cases and controls were not statistically significant. There was also no significant association between either homocysteine or Lp(a) and atherosclerotic disease, myocardial infarction or stroke in logistic regression analyses. The odds ratios varied from 1.00 to 1.26 for homocysteine and from 0.81 to 1.06 for Lp(a). The results of this prospective population-based study do not support the hypotheses that serum homocysteine or Lp(a) are risk factors for atherosclerotic disease. The lack of association between serum homocysteine and atherosclerotic disease may be due to the exceptionally low gene frequency predisposing to homocysteinemia in Finland.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8018111     DOI: 10.1016/0021-9150(94)90078-7

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  41 in total

Review 1.  Blood levels of homocysteine and atherosclerotic vascular disease.

Authors:  W G Christen; P M Ridker
Journal:  Curr Atheroscler Rep       Date:  2000-05       Impact factor: 5.113

Review 2.  Homocyst(e)ine and coronary heart disease: pharmacoeconomic support for interventions to lower hyperhomocyst(e)inaemia.

Authors:  Brahmajee K Nallamothu; A Mark Fendrick; Gilbert S Omenn
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

Review 3.  Lipoprotein(a): implications for clinical practice.

Authors:  Robert C Block; Thomas A Pearson
Journal:  Curr Atheroscler Rep       Date:  2005-09       Impact factor: 5.113

Review 4.  Nutrient supplements and cardiovascular disease: a heartbreaking story.

Authors:  Alice H Lichtenstein
Journal:  J Lipid Res       Date:  2008-11-06       Impact factor: 5.922

Review 5.  Novel markers of inflammation in atherosclerosis.

Authors:  Salim S Virani; Venkateshwar R Polsani; Vijay Nambi
Journal:  Curr Atheroscler Rep       Date:  2008-04       Impact factor: 5.113

6.  Homocysteine: the new player in the field of coronary risk.

Authors:  G Montalescot
Journal:  Heart       Date:  1996-08       Impact factor: 5.994

7.  Homocysteine and ischaemic stroke in men: the Caerphilly study.

Authors:  U B Fallon; P Elwood; Y Ben-Shlomo; J B Ubbink; R Greenwood; G D Smith
Journal:  J Epidemiol Community Health       Date:  2001-02       Impact factor: 3.710

8.  Homocysteine and coronary heart disease in the Caerphilly cohort: a 10 year follow up.

Authors:  U B Fallon; Y Ben-Shlomo; P Elwood; J B Ubbink; G D Smith
Journal:  Heart       Date:  2001-02       Impact factor: 5.994

9.  Plasma homocysteine, dietary B vitamins, betaine, and choline and risk of peripheral artery disease.

Authors:  Monica L Bertoia; Jennifer K Pai; John P Cooke; Michel M Joosten; Murray A Mittleman; Eric B Rimm; Kenneth J Mukamal
Journal:  Atherosclerosis       Date:  2014-04-28       Impact factor: 5.162

Review 10.  Homocysteine, MTHFR gene polymorphisms, and cardio-cerebrovascular risk.

Authors:  Elisabetta Trabetti
Journal:  J Appl Genet       Date:  2008       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.